Evidence map›Paper›PMID 34769152›Full record

ArticleInternational journal of molecular sciences2021

Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS.

Suran Nethisinghe, Rosella Abeti, Maheswaran Kesavan, W Christian Wigley, Paola Giunti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Suran NethisingheAtaxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.ORCID 0000-0002-4272-9292
Rosella AbetiAtaxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.
Maheswaran KesavanAtaxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.
W Christian WigleyReata Pharmaceuticals Inc., 2801 Gateway Drive, Irving, TX 75063, USA.
Paola GiuntiAtaxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG, UK.
National Hospital for Neurology and Neurosurgery · GBReata Pharmaceuticals (United States) · US

Funding

Ataxia Charlevoix-Saguenay Foundation N/AMedical Research Council MR/M02492X/1Medical Research Council MR/N028767/1
6 · The paper itself

Abstract

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurodegenerative disease caused by mutations in the

Indexed as

Cell LineCells, CulturedFibroblastsHSP90 Heat-Shock ProteinsHumansMitochondriaMuscle SpasticityNovobiocinSpinocerebellar AtaxiasVimentinHSP90 Heat-Shock ProteinsKU-32 compoundNovobiocinVimentinVIM protein, humanARSACSataxiaHsp90 inhibitionKU-32vimentin

Identifiers

PMID34769152
PMCPMC8584178
OpenAlexW3208477666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.